Goenka Business & Finance is a non-banking financial company that provides secured and unsecured loans and actively trades in equity shares and other financial instruments for its own account.
The company lacks a durable competitive advantage, as evidenced by extremely thin net margins (0.1%) and a business model heavily reliant on volatile proprietary stock trading and high-cost borrowings. The high ROCE is misleading due to the low equity base and high leverage, while the lack of pricing power is confirmed by the inability to maintain profitability when finance costs rise.
Management reinvests primarily into proprietary equity trading and high-risk unsecured loans. While the company turned a profit in FY26, the prior track record shows inconsistent returns and a lack of clear strategy for long-term value creation beyond market speculation.
The company's survival was cut short by the five-year SEBI market ban, which paralyzed its primary revenue engine of proprietary trading. With net margins already at a razor-thin 0.1%, the business could not absorb the 10 million INR penalty and rising finance costs. The high-risk unsecured loan portfolio suffered a wave of defaults, and without the ability to speculate in the securities market, the company bled out its remaining capital through overhead and tax demands, eventually becoming a shell of its former self.
RichFakir rates Goenka Business & Finance Ltd's business quality as poor — 8/100 on our quality score (profitability, growth, balance-sheet strength and capital allocation). We assess its competitive moat as none.
On our model, Goenka Business & Finance Ltd is trading about 26% below our estimate of fair value; we rate its price fair. This is an educational estimate from public filings, not a recommendation.
RichFakir's educational verdict on Goenka Business & Finance Ltd is: Not rated. Poor business (score 8), but the valuation is low-confidence, so we are not calling it a bargain.
RichFakir's educational estimate of Goenka Business & Finance Ltd's fair value is about ₹14 per share, derived from public filings. It's our estimate for research — not a price target or a recommendation to buy or sell.
View the full live analysis →